NCT03070392 · OUTCOME

Efficacy: Disease Control Rate (DCR)

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma · Source last updated 2026-03-17

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: DCR will be assessed every 3 months from randomization until disease progression, up to 5.5 years.

What was measured

Disease control rate (DCR) is defined as the proportion of patients with either an objective response or stable disease (RECIST v1.1)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Disease control rate (DCR) is defined as the proportion of patients with either an objective response or stable disease (RECIST v1.1)
reporting Status: NOT_POSTED
time Frame: DCR will be assessed every 3 months from randomization until disease progression, up to 5.5 years.
title: Efficacy: Disease Control Rate (DCR)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice